Icon completes Verisome PhIII; Indian scientists make cancer nanoparticles;

> Icon Bioscience reported that its Verisome delivery platform for post-cataract surgery inflammation has completed a Phase III study. Release

> A team at the Indian Institute of Science has developed nanocapsules to deliver cancer drugs. More

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.